26 Jan 2012 07:00
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Silence Therapeutics plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights YES An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Richard Bernstein (Pershingnotification obligation:iii Nominees and Hargreave Hale Nominees) 4. Full name of shareholder(s) Pershing Nominees and (if different from 3.):iv Hargreave Hale Nominees 5. Date of the transaction and date on which the threshold is crossed or 23thJanuary 2012 reached: v 6. Date on which issuer notified: 25th January 2012 7. Threshold(s) that is/are crossed or 4% reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type of Situation previous Resulting situation after the triggering transaction shares to the triggering transaction if possible Number Number Number Number of voting % of voting rightsusing of of of shares rights x the ISIN CODE Shares Voting Rights Direct Direct xi Indirect Direct Indirect xii GBP 1p ISIN: 18,440,000 3.20% 21,670,000 21,670,000 3.75% GB0008433350 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of voting instrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise Expiration Exercise/ Number of voting rights % of voting financial price date xvii Conversion instrument refers to rights xix, xx instrument period xviii CFD 4,185,000 Nominal Delta(Spread Bet) 0.73 Total (A+B+C) Number of voting rights Percentage of voting rights 25,855,000 4.48%
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: Richard Bernstein 15. Contact telephone number: 020 7478 9070
Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Richard Bernstein Contact address (registered office for legal entities) 29 Curzon Street, London W1J 7TL Phone number & email 020 7478 9070 Other useful information (at least legal representative for legal persons)
B: Identity of the notifier, if applicable Full name Richard Bernstein Contact address 29 Curzon Street, London W1J 7TL Phone number & email 020 7478 9070 - richard.bernstein@eurovestech.com Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information
For notes on how to complete form TR-1 please see the FSA website.
XLON